222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details
臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100050967 | 2021-09-30 | 2021-09-08 | A controlled clinical trial of the efficacy and safety of sacubitril/valsartan in reducing urinary protein in patients with low-risk membranous nephropathy | A controlled clinical trial of the efficacy and safety of sacubitril/valsartan in reducing urinary protein in patients with low-risk membranous nephropathy | membranous nephropathy | Experimental group:Conventional therapy+sacubitril/valsartan 100mg bid;Control group:Conventional therapy+valsartan 160mg qd; | China-Japan Friendship Hospital | NULL | Recruiting | 30 | 75 | Both | Experimental group:50;Control group:50; | Phase 4 | China |